REG - Wellnex Life Limited - Company Update

Wellnex LifeAnnouncement

22/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250922:nRSV2193Aa&default-theme=true

RNS Number : 2193A  Wellnex Life Limited  22 September 2025

 

 

 

ASX/AIM
Announcement
22 September 2025

 

 

Wellnex Life Limited (ASX/AIM:WNX)

 

 

Company Update

 

Wellnex Life Limited ("Wellnex" or the "Company") (ASX:WNX  AIM:WNX),  an
innovative consumer healthcare business with a track record for developing,
licensing, and marketing products and brands to customers in the growing
healthcare market segment, is pleased to provide the following company update.

Wellnex, through its wholly owned subsidiary BSPS Aust Pty Ltd, has received
the opening order from its global partner Haleon plc ("Haleon") for its TGA
registered Liquid Paracetamol and Ibuprofen softgel for the United Arab
Emirates (UAE). The UAE order opens a fourth national market (after Australia,
New Zealand and United Kingdom) in the Haleon global network that will be
supported by Wellnex Life and brings an additional product line to our
relationship with Haleon in addition to the already launched Liquid
Paracetamol softgel.

Whilst the terms of supply, via the Group's manufacturing partner to Haleon
remain confidential, the new agreement for the UAE will generate additional
revenue for the Company in the current financial year supporting our market
forecasts for the year. The launch of this second product validates Wellnex
Life's strategic focus on developing innovative consumer healthcare products
for its own brands and global supply partnerships.

Wellnex Life since 1 July 2025 has currently received confirmed purchase
orders from various contract manufacturing customers of c. $4.6 million. These
orders are all expected to be invoiced by no later than the end of December
2025. These confirmed purchase orders are in addition to the contract
manufacturing orders of c. $.800K already invoiced this financial year (total:
c. $5.4million) and revenues from the Company's other business operations.

Zack Bozinovski, Wellnex Life CEO, said: "We are again excited to see our
innovative TGA approved products being launched internationally with such a
valued global partner as Haleon. The launch of Liquid Paracetamol and
Ibuprofen softgel into the UAE builds on the existing supply agreement for the
Liquid Paracetamol softgel which has been supplied into the Australian, New
Zealand and United Kingdom markets. We look forward to continuing to partner
with global leaders such as Haleon on significant global distribution
opportunities for our products into the future."

This ASX/AIM announcement has been authorised by the Board of Wellnex Life
Limited (ASX/AIM:WNX).

For further information, please contact:

 

Wellnex Life Limited (ASX:WNX)
                                 Reach Markets

Zack
Bozinovski
                          T: 1300 805 795

Chief Executive
Officer
             E: IR@reachmarkets.com.au
(mailto:IR@reachmarkets.com.au)

P: +61 3 8399 9419

E: zack.b@wellnexlife.com.au (mailto:zack.b@wellnexlife.com.au)

 

UK Investors

 

Strand Hanson (Financial & Nominated Advisor)

James Harris / Richard Johnson
            Tel: +44 (0) 20 7409 3494

 

Orana Corporate LLP (Joint
Broker)
swykeham@oranacorp.com (mailto:swykeham@oranacorp.com)

Sebastian Wykeham

 

S.P. Angel Corporate Finance LLP (Joint Broker)        Tel: +44 (0)20
3470 0470

David Hignell / Vadim Alexandre

 

 

About Wellnex Life

 

Wellnex Life Limited (ASX/AIM:WNX) is a consumer healthcare business with a
track record for developing, licensing, and marketing registered products and
brands to customers in the growing healthcare market segment. Since listing on
ASX in 2021, Wellnex Life has successfully launched a host of brands and
products now ranged in major retailers in the healthcare market space,
pharmacies and supermarkets. Its distribution arrangements have seen Wellnex
Life secure significant licensing arrangements with major pharmaceutical
companies in Australia and globally that have given the Company's registered
products a distribution channel with a steadily increasing global geographic
footprint.

 

In December 2023, Wellnex Life acquired leading Australian topical pain relief
brand Pain Away. Its addition to Wellnex Life's product offering both
compliments and accelerates the potential growth of the company's business
operations. This transformational acquisition gives added impetus to Wellnex
Life's financial growth and scale and reinforces its place as a major and
respected participant in the growing healthcare market, both in Australia and
overseas.

 

The information contained within this announcement is deemed by the Company to
constitute inside information pursuant to article 7 of EU Regulation 596/2014
as it forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 as amended.

 

To learn more, please visit: www.Wellnex Lifelife.com.au/
(https://wellnexlife.com.au/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDELLBLEKLEBBF



            Copyright 2019 Regulatory News Service, all rights reserved